Fig 1.
Decision-analytic tree (1) and Markov transitional states (2).
P1: probability of high-risk group for moderate to severe ototoxicity (GSTP1 c.313 AG/GG genotypes); P2: probability of death or loss to follow-up during therapy in cisplatin-treated patients; P3: probability of death or loss to follow-up during therapy in docetaxel-treated patients; P4: probability of moderate to severe ototoxicity in the conventional arm; P5: probability of moderate to severe ototoxicity in low-risk patients treated with cisplatin; P6: probability of moderate to severe ototoxicity in high-risk patients treated with docetaxel; T1: transitional probability for death; T2: transitional probability for hearing loss in asymptomatic individuals. A: adenine; CDDP: cisplatin; G: guanine; GSTP1: glutathione transferase P1 gene; RT: radiotherapy.
Table 1.
Summarized data on cost inputs.
Table 2.
Markov Chain Monte Carlo simulations.
Fig 2.
Graphical representation of the total costs in the first year for the conventional arm and GSTP1 c.313A > G genotyping and the cost reduction, based on the number of simultaneous samples (3 samples in A, 5 samples in B) and the cumulative volume of analyzed patients.
US$: United States Dollars.
Table 3.
Total costs per patient in the first year for the GSTP1 c.313A > G genotyping group and the differences compared to the conventional arm, considering simultaneous genotyping of three samples.
Table 4.
Cost reduction associated with the use of GSTP1 c.313A > G genotyping over a ten-year follow-up period, considering genotyping with three samples in a population of 250 patients.